Fisher & Paykel Healthcare to Announce Half Year Results on 22 November 2013

Fisher & Paykel Healthcare Corporation Limited (NZSX:FPH, ASX:FPH) announced today that it intends to release on Friday, 22 November 2013 its financial results for the six months ended 30 September 2013. The release will be issued shortly after 9:00am NZDT, 7:00am AEDT (3:00pm USEST, Thursday, 21 November).

Fisher & Paykel Healthcare will host a conference call on Friday, 22 November 2013 to review the results and to discuss the outlook for the remainder of the 2014 financial year. The conference call is scheduled to begin at 10:00am NZDT, 8:00am AEDT (4:00pm USEST, Thursday, 21 November) and will be broadcast simultaneously over the Internet.

To listen to the webcast, access the company’s website at Please allow extra time prior to the webcast to visit the site and download the streaming media software if required. An online archive of the event will be available approximately two hours after the webcast and will remain on the site for two weeks.

To attend the conference call, participants will need to dial in to one of the numbers below at least 5 minutes prior to the scheduled call time and identify yourself to the operator. When prompted, please quote the conference code of: 94752676.

New Zealand Toll Free 0800 446 046 USA Toll Free 1855 415 1161
Australia Toll Free 1800 725 000 Hong Kong Toll Free 800 968 831
United Kingdom Toll Free 0808 234 1369 International +61 2 8373 3610

An audio replay of the conference call will be available approximately 2 hours after the call and will be accessible for two weeks by dialing one of the numbers below. When prompted please enter the conference code of: 94752676.

New Zealand Toll Free 0800 453 213 USA Toll Free 1855 452 5696
Australia Toll Free 1800 153 898 Hong Kong Toll Free 800 963 117
United Kingdom Toll Free 0808 234 0072 International +61 2 8199 0299


About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. The company’s products are sold in more than 120 countries worldwide. For more information about the company, visit our website

Contact: Michael Daniell MD/CEO on +64 9 574 0161 or Tony Barclay CFO on +64 9 574 0119.